

Amnt G/#13
10/16/03

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 872-9907, on the date shown below.

Dated: August 21, 2003

Signature: 

(James W. Brady, Jr.)

Docket No.: A7542.0000/P001-E
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ginette Serrero

Confirmation No.: 2662

Application No.: 09/824,647

Art Unit: 1642

Filed: April 4, 2001

Examiner: M. Yu

For: 88KDA TUMORIGENIC GROWTH
FACTOR AND ANTAGONISTSAMENDMENT AFTER FINAL ACTION (37 C.F.R. SECTION 1.116)MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated July 15, 2003 (Paper No. 12), indicating the allowability of claims 28-49 and 56-75, and finally rejecting claims 50-55, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 7 of this paper.

OFFICIAL

FAX RECEIVED
AUG 22 2003
GROUP 1600

FAX TRANSMISSION**DATE:** August 21, 2003**PTO IDENTIFIER:** Application Number 09/824,647-Conf. #2662
Patent Number**Inventor:** Ginette Serrero**MESSAGE TO:** Examiner Misook Yu**FAX NUMBER:** 703-872-9307**FROM:** DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP

James W. Brady, Jr.

PHONE: (202) 775-4786**Attorney Dkt. #:** A7542.0000/P001-E**PAGES (Including Cover Sheet):** 10**CONTENTS:** Amendment After Final Action (37 C.F.R. Section 1.116) (7 pages) and
Amendment Transmittal (1 page).

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (202) 775-4786 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP
2101 L Street NW, Washington, DC 20037-1526
Telephone: (202) 785-9700 Facsimile: (202) 887-0689

PTO/SB/97 (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Certificate of Transmission Under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on August 21, 2003
Date





Signature

James W. Brady, Jr. (32,115)
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Amendment After Final Action (37 C.F.R. Section 1.116) (7 pages) and
Amendment Transmittal (1 page).

AMENDMENT TRANSMITTAL LETTER				Docket No. A7542.0000/P001-E	
Application No. 09/824,647-Conf. #2662		Filing Date April 4, 2001		Examiner M. Yu	
Art Unit 1642					
Applicant(s): Ginette Serrero					
Invention: 88KDA TUMORIGENIC GROWTH FACTOR AND ANTAGONISTS					
TO THE COMMISSIONER FOR PATENTS					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	42	- 48 =		x	0.00
Independent Claims	4	- 5 =		x	0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00
<input checked="" type="checkbox"/> Large Entity <input type="checkbox"/> Small Entity					
<input checked="" type="checkbox"/> No additional fee is required for this amendment.					
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of \$ _____ A duplicate copy of this sheet is enclosed.					
<input type="checkbox"/> A check in the amount of \$ _____ to cover the filing fee is enclosed.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>04-1073</u> as described below. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> Credit any overpayment.					
<input checked="" type="checkbox"/> Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.					
 James W. Brady, Jr. Attorney Reg. No.: 32,115 DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP 2101 L Street NW Washington, DC 20037-1526 (202) 775-4786				Dated: <u>August 21, 2003</u>	
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 872-8307, on the date shown below.					
Dated: August 21, 2003		Signature:  (James W. Brady, Jr.)			

FAX RECEIVED
AUG 22 2003
GROUP 1600

OFFICIAL